Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Movetis

Movetis
2006 FOUNDED
M&A STATUS
21-30 EMPLOYEES
M&A LATEST DEAL TYPE
$528M LATEST DEAL AMOUNT
Description

Developer of drugs for the treatment of diseases in the gastrointestinal (GI) area. The company's products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. Its lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women.

Website
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • Veedijk 58 1004
  • 2300 Turnhout
  • Belgium

+32 014 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Movetis’s full profile, request a free trial.

Movetis Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 09-Nov-2010 $528M 00000 00000 Completed Generating Revenue
2. IPO 03-Dec-2009 00000 00000 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 08-Jan-2007 $64.4M $64.4M Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Movetis Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
BIP Investment Partners PE/Buyout Minority 000 0000 000000 0
Gimv PE/Buyout Minority 000 0000 000000 0
KBC Group Corporation Minority 000 0000 000000 0
Life Sciences Partners Venture Capital Minority 000 0000 000000 0
Quest For Growth Asset Manager Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »